Document Detail


Lower extremity ulcers in rheumatoid arthritis: features and response to immunosuppression.
MedLine Citation:
PMID:  21340497     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lower extremity ulcers are a recognized complication of rheumatoid arthritis (RA). Their prevalence has not been assessed since the advent of more aggressive disease modifying antirheumatic therapies. The purpose of this study was to establish the period prevalence of lower extremity ulcers in a modern-day unselected cohort of patients with RA, and to report the features associated with ulcer development and response to therapy. Between June 2007 and June 2010, 366 RA patients were evaluated at the Georgetown Division of Rheumatology. Data were collected and analyzed retrospectively on demographics, antibody and prothrombotic profile, comorbidities, disease activity, and outcomes. The period prevalence of ulcers in this cohort of 366 patients with RA followed over 3 years was 4.37%. Patients with ulcers were predominantly female (81.25%) and more commonly African American (56.2%). The mean disease duration at ulcer development was 25.9 years. All patients with ulcers had erosive disease and 63% were seropositive. Only five patients (31.25%) healed over a mean follow-up of 22.8 months. However, in this small sample, treatment with anti-tumor necrosis factor-α (anti-TNFα) therapy was associated with significantly higher likelihood of healing (p = 0.039). In this modern-day cohort of patients with RA, we found a prevalence of lower extremity ulcers of 4.37% over 3 years. Only 31.25% of patients healed after a mean 22.8 months of follow-up. However, treatment with a biologic agent was associated with a significant increased likelihood of healing (RR 3.27, 95% CI 0.59-18.29, p = 0.039).
Authors:
Victoria K Shanmugam; David M DeMaria; Christopher E Attinger
Related Documents :
526877 - Cardiac response of nigerian hypertensives to anaesthesia and surgery.
3159517 - The influence of monotherapy with oxprenolol and nitrendipine on ambulatory blood press...
1188287 - Diagnostic value of renography for detection of unilateral renal or renovascular diseas...
15480107 - Does comorbidity explain trends in prescribing of newer antihypertensive agents?
14763887 - Nail involvement in leprosy: a study of 300 patients.
24685817 - Risk prediction with proprotein convertase subtilisin/kexin type 9 (pcsk9) in patients ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-02-22
Journal Detail:
Title:  Clinical rheumatology     Volume:  30     ISSN:  1434-9949     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-05-25     Completed Date:  2011-09-22     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  849-53     Citation Subset:  IM    
Affiliation:
Division of Rheumatology, Immunology and Allergy, Georgetown University Hospital, NW Washington, DC 20007, USA. vks4@gunet.georgetown.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
African Continental Ancestry Group
Aged
Antibodies, Anticardiolipin / blood
Antibodies, Antiphospholipid / blood
Antirheumatic Agents / pharmacology,  therapeutic use*
Arthritis, Rheumatoid / blood,  complications*,  ethnology
Biopsy
Cohort Studies
European Continental Ancestry Group
Female
Follow-Up Studies
Humans
Immunosuppressive Agents / pharmacology,  therapeutic use*
Leg Ulcer / drug therapy*,  epidemiology,  etiology*
Male
Middle Aged
Prevalence
Retrospective Studies
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Wound Healing / drug effects
Grant Support
ID/Acronym/Agency:
KL2 RR031974-01/RR/NCRR NIH HHS; KL2RR031974/RR/NCRR NIH HHS; UL1 RR031975-01/RR/NCRR NIH HHS; UL1RR031975/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Anticardiolipin; 0/Antibodies, Antiphospholipid; 0/Antirheumatic Agents; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of anticyclic citrullinated peptide antibodies with extra-articular manifestations, gend...
Next Document:  Serum heat shock protein 60 can predict remission of flare-up in juvenile idiopathic arthritis.